Vitamin K1

Jaundice, Obstructive, long-acting anticoagulant rodenticides, Vitamin K Deficiency + 17 more

Treatment

10 FDA approvals

19 Active Studies for Vitamin K1

What is Vitamin K1

Phylloquinone

The Generic name of this drug

Treatment Summary

Vitamin K1, also known as phylloquinone or phytonadione, is a type of fat-soluble vitamin used since 1939. It helps the body form blood clotting factors and is used to treat coagulation disorders caused by a vitamin K deficiency. Vitamin K1 has been approved by the FDA since 1955.

Mephyton

is the brand name

image of different drug pills on a surface

Vitamin K1 Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Mephyton

Phylloquinone

1955

65

Approved as Treatment by the FDA

Phylloquinone, also known as Mephyton, is approved by the FDA for 10 uses including Jaundice, Obstructive and Hypoprothrombinemia .

Jaundice, Obstructive

Used to treat Jaundice, Obstructive in combination with Taurocholic acid

Hypoprothrombinemia

Fistula, Biliary

Used to treat Fistula, Biliary in combination with Taurocholic acid

antibacterial therapy

Biliary Fistula

Used to treat Fistula, Biliary in combination with Taurocholic acid

hemorrhagic disease of the newborn

Hypoprothrombinemias

Jaundice, Obstructive

Used to treat Jaundice, Obstructive in combination with Taurocholic acid

Hemorrhagic Disease of Newborn

Salicylate

Effectiveness

How Vitamin K1 Affects Patients

Phylloquinone is a type of vitamin K that can help treat blood clotting issues caused by a vitamin K deficiency. It stays in the body for a long time, so it only needs to be taken occasionally. Most people can tolerate large doses of this vitamin, but it's important to monitor prothrombin time while taking it and be aware of the risk of allergic reactions when given through a needle.

How Vitamin K1 works in the body

Vitamin K helps the body form blood clots. It does this by attaching carboxylic acid groups to a molecule called glutamate, which helps clotting factors bind to calcium. These clotting factors are released from the liver, restoring normal clotting. Vitamin K may also help protect joints from calcification, increase type two collagen and help with bone density. Researchers are still investigating its effects on arthritis, bone density and artery calcification.

When to interrupt dosage

The dose of Vitamin K1 is contingent upon the diagnosed condition, including Sprue, Vitamin supplementation and Ulcerative Colitis. The magnitude of dosage is subject to the application method itemized in the table below.

Condition

Dosage

Administration

Biliary Fistula

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Ulcerative Colitis

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Vitamin supplementation

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

long-acting anticoagulant rodenticides

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Anticoagulant Therapy

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Vitamin supplementation therapy

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

hemorrhagic disease of the newborn

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

vitamin K

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Crohn Disease

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Blood Coagulation Disorders

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Celiac Disease

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Jaundice, Obstructive

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Vitamin K Deficiency

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Hypoprothrombinemias

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Intestinal resection

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Hemorrhagic Disease of Newborn

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Salicylate

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Cystic Fibrosis

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Celiac Disease

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

antibacterial therapy

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Intramuscular; Parenteral; Subcutaneous, Injection, solution, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Emulsion, Intramuscular, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution - Intravenous, Intravenous, Solution - Parenteral, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous, Liquid, Liquid - Intravenous, Kit, Kit - Oral, Capsule - Oral, Capsule, Injection - Intravenous, Injection, Solution, Solution / drops, Solution - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous

Warnings

Vitamin K1 Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Phylloquinone may interact with Pulse Frequency

There are 20 known major drug interactions with Vitamin K1.

Common Vitamin K1 Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Phylloquinone.

(S)-Warfarin

Major

The therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Phylloquinone.

4-hydroxycoumarin

Major

The therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Phylloquinone.

Acenocoumarol

Major

The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Phylloquinone.

Clorindione

Major

The therapeutic efficacy of Clorindione can be decreased when used in combination with Phylloquinone.

Vitamin K1 Toxicity & Overdose Risk

Taking too much vitamin K1 can be dangerous, especially when given through an IV. The toxic dose of vitamin K1 for mice is 1170 mg/kg when given intravenously and more than 24180 mg/kg when given orally. If someone overdoses on vitamin K1, they should be treated with supportive care.

image of a doctor in a lab doing drug, clinical research

Vitamin K1 Novel Uses: Which Conditions Have a Clinical Trial Featuring Vitamin K1?

At present, 100 active studies are in progress to evaluate the potential of Vitamin K1 in addressing Crohn Disease, Hemorrhagic Disease of the Newborn and Obstructive Jaundice.

Condition

Clinical Trials

Trial Phases

Ulcerative Colitis

17 Actively Recruiting

Phase 3, Phase 2, Phase 1, Not Applicable, Phase 4

Jaundice, Obstructive

0 Actively Recruiting

Blood Coagulation Disorders

0 Actively Recruiting

Cystic Fibrosis

0 Actively Recruiting

Vitamin K Deficiency

0 Actively Recruiting

Vitamin supplementation

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

antibacterial therapy

0 Actively Recruiting

Hemorrhagic Disease of Newborn

0 Actively Recruiting

Celiac Disease

0 Actively Recruiting

Hypoprothrombinemias

0 Actively Recruiting

vitamin K

0 Actively Recruiting

hemorrhagic disease of the newborn

0 Actively Recruiting

Vitamin supplementation therapy

0 Actively Recruiting

long-acting anticoagulant rodenticides

0 Actively Recruiting

Celiac Disease

0 Actively Recruiting

Salicylate

0 Actively Recruiting

Anticoagulant Therapy

2 Actively Recruiting

Phase 4, Not Applicable

Intestinal resection

0 Actively Recruiting

Biliary Fistula

0 Actively Recruiting

Patient Q&A Section about vitamin k1

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which is better to take vitamin K1 or K2?

"Several studies have suggested that vitamin K2 is better than K1 at reducing calcium deposits and lowering your risk of heart disease."

Answered by AI

Is vitamin K1 the same as vitamin K?

"Vitamin K1 is the main form of vitamin K in the diet. It's found in green vegetables and in plant chlorophylls. Vitamin K2 is made by bacteria and is found in food where bacteria are part of the production process."

Answered by AI

What is vitamin K1 and K2 good for?

"There are two types of vitamin K, K1 and K2. Both are important for blood clotting and preventing excessive bruising and bleeding. However, recent research suggests that K2 may offer additional health benefits beyond those of K1."

Answered by AI

What is vitamin K1 used for?

"Vitamin K is essential for blood clotting, bone building, and other important processes. There are two main types of vitamin K: K1 (phytonadione) and K2 (menaquinone). Vitamin K1 is found in green vegetables, while vitamin K2 is commonly available as a supplement."

Answered by AI

Clinical Trials for Vitamin K1

Image of McMaster Children's Hospital - Digestive Diseases Clinic in Hamilton, Canada.

Vancomycin for Ulcerative Colitis

18+
All Sexes
Hamilton, Canada

This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition. The main questions it aims to answer are: * Can oral vancomycin improve UC symptoms as measured by Mayo score at 4 weeks? * Is oral vancomycin safe and tolerable in this patient group? Participants will be compared to see if vancomycin works better than placebo. Participants will: * Take oral vancomycin (250 mg twice daily) or identical placebo capsules for 4 weeks * Have the option for 4 more weeks of open-label vancomycin after the blinded phase * Attend clinic visits at baseline, week 4, and follow-up for Mayo scoring, endoscopy, blood/stool tests, and safety checks * Track treatment adherence and side effects The study primarily assesses if the trial can recruit 14 participants, retain them, achieve good adherence, and follow protocol procedures (feasibility). Secondary goals include safety (adverse events) and early signs of benefit in UC activity, liver tests, and gut bacteria balance. This pilot will guide larger future studies.

Phase 2
Waitlist Available

McMaster Children's Hospital - Digestive Diseases Clinic

Neeraj Narula, MD

Image of MUHC - Montreal General Hospital in Montreal, Canada.

Ustekinumab for Crohn's Disease and Ulcerative Colitis

18+
All Sexes
Montreal, Canada

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST). The main question it aims to answer is: Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflammation markers and intestinal mucosa integrity and to see if UST dose can be reduced while maintaining clinical remission. Participants will: Change UST dosing from Q4 to Q8 or from Q8 to Q12. Visit the clinic once every 12 weeks for checkups and tests.

Phase 4
Recruiting

MUHC - Montreal General Hospital

Janssen Inc.

Have you considered Vitamin K1 clinical trials?

We made a collection of clinical trials featuring Vitamin K1, we think they might fit your search criteria.
Go to Trials
Image of Rubix LS in Lawrence, United States.

Mirikizumab for Inflammatory Bowel Disease

60 - 99
All Sexes
Lawrence, MA

This research study looks at how safe and effective a medicine called Mirikizumab is for treating older adults (aged 60 and above) who have moderate to severe Crohn's disease (CD) or ulcerative colitis (UC). These two conditions, known as inflammatory bowel diseases (IBD), cause inflammation (swelling and irritation) in the digestive tract. Older adults with these conditions often have other health issues and face increased risks and complications, making it challenging for them to use certain treatments. Mirikizumab is already approved by the FDA for adults with IBD, but there's limited information about how well it works specifically for older adults. This study aims to fill that gap by seeing if Mirikizumab can help these patients safely manage their condition. The study plans to enroll around 150 people from various locations across the United States. Everyone participating will receive Mirikizumab according to the standard, FDA-approved guidelines. The main goal is to see how many participants achieve clinical remission, meaning their symptoms significantly improve or disappear, after 24 weeks of treatment. Researchers will also look at whether this remission lasts up to 48 weeks, how well symptoms are controlled without steroids, how treatment affects indicators of inflammation (such as blood tests), and how the participants feel overall based on their own reports. The safety of Mirikizumab will also be closely monitored throughout the study by regularly checking for any side effects. This study hopes to provide clearer information to help older adults with IBD and their doctors make better treatment decisions, ultimately improving health outcomes and quality of life.

Phase 4
Waitlist Available

Rubix LS

Eli Lilly and Company

Image of Toronto Immune and Digestive Health Institute in North York, Canada.

Healing Circuits™ for Inflammatory Bowel Disease

18 - 75
All Sexes
North York, Canada

The purpose of this study is to test the impact of Healing Circuits™; a structured mental health support model on IBD patients. The eligible study participants will be randomly divided into two groups: 1. the group receiving structured mental health support with a social worker and 2. the group receiving structured mental health support via a self-directed online curriculum. Both groups will be receiving the same type of therapy, Healing Circuits™, but the group receiving the therapy via the online self-directed curriculum will be receiving the therapy mostly by web-based video instruction. The two groups will be evaluated over a period of 12 months.

Recruiting
Has No Placebo

Toronto Immune and Digestive Health Institute

Mark Silverberg, MD, PhD

Amgen

Image of Carolina Digestive Diseases- Site Number : 8400013 in Greenville, United States.

SAR441566 for Ulcerative Colitis

18 - 75
All Sexes
Greenville, NC

This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. * The study duration will be up to 59 weeks. * The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm. * The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.

Phase 2
Recruiting

Carolina Digestive Diseases- Site Number : 8400013 (+28 Sites)

Sanofi

Have you considered Vitamin K1 clinical trials?

We made a collection of clinical trials featuring Vitamin K1, we think they might fit your search criteria.
Go to Trials
Image of University of Chicago in Chicago, United States.

Therapy De-escalation for Ulcerative Colitis

18 - 75
All Sexes
Chicago, IL

The goal of this study is to better understand treatment strategies for people with ulcerative colitis (UC). Researchers will compare patients with UC in histologic remission (no evidence of inflammation or active disease on endoscopy and biopsies) who continue to take medical therapy to patients with UC who de-escalate (decrease or discontinue) medical therapy. Both treatment strategies are considered within regular medical practice. Researchers want to find out whether remission can be maintained after de-escalation of therapy. Participants will be: * either be randomly assigned to continue medical therapy or de-escalate medical therapy -OR- be assigned per the participant's preference * clinically managed according to regular medical care * asked to provide blood, stool (poop), and tissue samples for study purposes

Recruiting
Has No Placebo

University of Chicago

David T Rubin, MD

Image of University of Colorado. School of Medicine in Denver, United States.

Decision-Making Tool for Blood Thinners

18+
All Sexes
Denver, CO

The purpose of this project is to implement and evaluate a shared-decision making (SDM) tool called DDInteract that was developed to support decision making for drug-drugs interactions while on oral anticoagulants. DDInteract will be implemented in clinics at the University of Utah, University of Colorado and University of Vanderbilt. DDInteract will be launched from within the electronic health record (EHR) retrieving patient-specific risk factors, will calculate the risk of harm, and will allow providers and patients to dynamically explore "what if" scenarios to optimize treatment and minimize risk. DDInteract will enable shared-decision making using individually-tailored information on the potential benefits and harms of drug interactions in anticoagulated patients.

Recruiting
Has No Placebo

University of Colorado. School of Medicine (+2 Sites)

Daniel C Malone, PhD

Have you considered Vitamin K1 clinical trials?

We made a collection of clinical trials featuring Vitamin K1, we think they might fit your search criteria.
Go to Trials